GLP-1 claims on natural health products are appearing more frequently as consumer interest in metabolic health and weight management continues to grow. If your company plans to launch an NHP that references GLP-1, appetite regulation, or blood glucose support, it’s important to understand where Health Canada draws the line. Misjudging that boundary can cost you your NPN licence, delay your product launch, or trigger enforcement action.
The challenge is that the distinction between a permissible NHP claim and a claim that may be considered to represent a drug-like therapeutic effect is not always obvious. Health Canada regulates natural health products under the Natural Health Products Regulations (NHPR), and the regulations around therapeutic claims are much stricter.
Understanding what language you can support before you finalize your claims or submit your product licence application can help avoid unnecessary revisions, delays, and costs. This post looks at what to consider when developing claims for NHPs that reference GLP-1, appetite regulation, blood glucose, or related metabolic functions — and what to check before you put those claims on your label or marketing materials.
Why GLP-1 Language Is Attracting Regulatory Scrutiny
GLP-1, or glucagon-like peptide-1, is a hormone involved in insulin secretion, appetite regulation, and blood glucose control. Pharmaceutical GLP-1 receptor agonists such as semaglutide have become widely known, and this public awareness has created significant commercial interest in the broader GLP-1 and metabolic health space. Canadian retailers and publishers are already promoting GLP-1 supplements for weight management and blood sugar support. This may pressure NHP brands to use similar language in their product names, labels, and marketing materials.
In January 2026, Health Canada issued a public advisory on unauthorized GLP-1 products. It reported retailers selling them in stores and online. The advisory stated that Health Canada was actively monitoring the marketplace and taking compliance action, including seizures and compliance or warning letters.
The advisory specifically addresses drugs, rather than NHPs making GLP-1-related claims. However, it demonstrates Health Canada’s active attention to the broader GLP-1 marketplace. For NHP brands operating in this space, it is therefore important to be careful about how GLP-1, appetite, blood glucose, and weight-management concepts are represented.
What Health Canada Permits for NHP Claims
Health Canada approves NHP claims based on the product’s evidence, the applicable monograph (where one exists), and the specific language of the claim itself. You cannot sell NHPs in Canada without a product licence. Health Canada then issues a natural product number (NPN), which indicates the product is authorized for sale under its approved conditions of use. Our guide explains what an NPN is and why it matters.
For products that affect appetite, blood sugar, or metabolic function, you can review the compendium of Health Canada monographs to identify pre-cleared wording for specific ingredients.
Where a product meets the applicable monograph requirements, using monograph-supported claims can simplify the licensing process and reduce the need for additional product-specific evidence. However, the claim must still align with the ingredient, dose, route of administration, dosage form, and other conditions specified in the applicable monograph.
How to Check Whether a Claim Has Support
Start with monographs for the ingredient of interest. They provide pre-cleared information for specific ingredients used under conditions established by Health Canada. This means that, when a product meets the applicable monograph requirements, you may not need to develop the same level of product-specific evidence from scratch.
- Search for your medicinal ingredient in the NHPID database.
- Review the applicable monograph, including the approved uses, doses, routes of administration, dosage forms, and other conditions.
- Compare each proposed claim against the specific wording and conditions in the monograph.
- Flag any claim that goes beyond what the monograph says.
A monograph applies only when its specified conditions are met. This means you need to consider not only the ingredient itself, but also the dose, source, route of administration, dosage form, and intended use. A monograph may also provide no support for a particular GLP-1 related use or claim. If no applicable monograph supports your proposed claim, speak with a regulatory professional about the available evidence and potential licensing pathway.
The application class also affect the evidence requirements and anticipated review timeline, so it is important to consider this early in the product development process. Our guide to NHP Class I, II, and III explains the differences. For more on monographs, see our guide to NNHPD monographs.
What Health Canada Does Not Permit
Health products in Canada must be authorized for sale before they are advertised, and their claims must not be false, misleading, or deceptive. Brands also cannot suggest government approval or endorsement. Health Canada does not endorse individual health products, and its logo cannot be used in advertising in a way that implies it does.
For GLP-1-related products, the bigger risk is in disease-related and comparative wording. Prescription GLP-1 drugs are authorized to treat type 2 diabetes and obesity, but an NHP should not imply that it treats or manages a disease unless that claim is specifically authorized for the product. Wording that suggests an NHP “works like” a GLP-1 drug, produces the same effects, or directly activates GLP-1 pathways can also raise concerns, because it may imply a drug-like effect that the product’s evidence or licence does not support.
These limits apply to the whole product presentation, not just the label. Health Canada looks at how a product is presented overall, so your product name, headlines, website copy, ads, and social posts all count. Before you publish GLP-1-related marketing, have that full presentation reviewed from a regulatory perspective.
Marketing Language Outside the Label Also Counts
A common mistake is assuming that Health Canada’s requirements stop at the label. They do not. Health Canada’s guidance on advertising applies to health-related representations in any media, so your website, social posts, ads, retailer listings, and other promotional materials are all relevant from a regulatory perspective.
Across all of these channels, your marketing should stay consistent with the product’s authorized conditions of use. It should not add claims or representations that go beyond what the licence supports. For example, if your website makes a GLP-1-related claim that doesn’t appear on the label, review that wording for compliance.
Digital marketing teams often move quickly, so adding a regulatory review step to your content process helps catch issues before publication.
How the Product Licence Application Process Applies Here
When you submit a Product Licence Application, Health Canada assesses the proposed conditions of use, including the medicinal ingredients, doses, recommended uses, and supporting evidence. If your application refers to GLP-1 activity, or makes a claim about appetite, blood glucose, weight management, or metabolic function, review the wording and evidence carefully before you submit. Catching problem wording and evidence gaps at this stage can reduce regulatory back-and-forth later.
Once an NPN is issued, the product must be marketed consistently with its authorized conditions of use. The approved claims become your reference point for consumer-facing marketing, which helps you avoid revising materials after launch.
Our team supports NHP licensing, including NPN applications and label compliance. For website and social media content, our advertising and media compliance service reviews claims and promotional materials against Health Canada and FDA requirements.
Key Takeaways
- GLP-1 claims require careful review. NHP marketing should avoid implying that an NHP provides the same therapeutic effects, unless the representation is specifically authorized.
- Your product licence and authorized conditions of use, including claims, set the boundary for your marketing.
- Comparisons to prescription GLP-1 drugs require particular care as they may create additional regulatory concerns and should be reviewed before publication.
- Health Canada’s advertising requirements apply beyond the label. Websites, social media, retailer listings, and other consumer-facing materials must comply with applicable requirements as well.
- Reviewing claim language before you file helps you catch problems early.
Frequently Asked Questions
Can I mention GLP-1 anywhere on my NHP product without triggering a drug classification?
It depends on the wording, context, and how you represent the product overall. Health Canada's advertising guidance covers health-related messages on any media, including digital platforms. This means you should review your website and social media content as carefully as your product label. Even an educational mention can shape how readers see your product. A cautious approach is to keep consumer-facing copy anchored to your product’s authorized claims and consider having a regulatory expert review any GLP-1-related references before you publish.
Does my NPN mean my GLP-1 marketing is approved?
No. An NPN indicates that Health Canada has authorized the NHP for sale under its approved conditions of use. It does not mean that every subsequent advertisement or marketing representation is automatically approved. Any advertising must still avoid being false, misleading, or deceptive. The industry is also responsible for meeting the federal advertising requirements and reviewing your authorized claims.
Should I use an advertising preclearance agency?
Adverting preclearance is voluntary, but Health Canada strongly recommends that companies use preclearance services for consumer-directed health product advertising. Independent agencies review consumer-directed advertising for natural health products. You can pair a preclearance review with a claims review to assess the scientific and regulatory support for your proposed messaging. Health Canada lists the agencies on its advertising preclearance page.
Planning Your NHP Claims Before You File
Your product licence sets the authorized conditions of use for your NHP, including its claims, and your marketing needs to stay accurate and consistent with them. GLP-1 wording needs extra care, because prescription GLP-1 drugs are authorized for specific medical conditions.
If you are planning an NHP positioned around appetite, blood sugar, or metabolic health, reviewing your proposed claims early can help you find potential regulatory concerns before submission. Our team can help you assess your claim approach and regulatory pathway. Learn more about our Canada NHP licensing services, or contact us to talk through your plan before you file.
